Diplomat Pharmacy, Inc. is dispensing Exelixis' limited-distribution treatment CABOMETYX® (cabozantinib), now with an expanded indication. CABOMETYX was recently approved by the Food and Drug Administration as a first-line therapy indicated to treat patients with advanced renal cell carcinoma (RCC). CABOMETYX was initially approved as a second-line therapy for advanced RCC in 2016. RCC is a type of cancer in which malignant cells form in the lining of tubules of the kidney. According to the American Cancer Society, RCC is the most common form of kidney cancer found in adults, accounting for nearly 90% of all kidney cancers.